Duncan Keeble

Renephra Ltd. develops medical devices. Its is developing ground-breaking new approaches to dialysis treatment in end-stage renal disease by accessing the interstitial fluid in the skin. This new approach enables water and toxin removal in a non-invasive manner. The company was founded by Paul Brenchley and Sandip Mitra in 2009 and is headquartered in Manchester, the United Kingdom.

Renephra Ltd. develops medical devices. Its is developing ground-breaking new approaches to dialysis treatment in end-stage renal disease by accessing the interstitial fluid in the skin. This new approach enables water and toxin removal in a non-invasive manner. The company was founded by Paul Brenchley and Sandip Mitra in 2009 and is headquartered in Manchester, the United Kingdom.

Renephra Ltd. develops medical devices. Its is developing ground-breaking new approaches to dialysis treatment in end-stage renal disease by accessing the interstitial fluid in the skin. This new approach enables water and toxin removal in a non-invasive manner. The company was founded by Paul Brenchley and Sandip Mitra in 2009 and is headquartered in Manchester, the United Kingdom.

Renephra Ltd. develops medical devices. Its is developing ground-breaking new approaches to dialysis treatment in end-stage renal disease by accessing the interstitial fluid in the skin. This new approach enables water and toxin removal in a non-invasive manner. The company was founded by Paul Brenchley and Sandip Mitra in 2009 and is headquartered in Manchester, the United Kingdom.

Renephra Ltd. develops medical devices. Its is developing ground-breaking new approaches to dialysis treatment in end-stage renal disease by accessing the interstitial fluid in the skin. This new approach enables water and toxin removal in a non-invasive manner. The company was founded by Paul Brenchley and Sandip Mitra in 2009 and is headquartered in Manchester, the United Kingdom.